Financial Data and Key Metrics Changes - Total company revenue for Q2 2023 was $1.035 billion, reflecting a growth of 12% on a constant currency basis and 10% on a reported basis compared to the prior year [18][36] - Adjusted EBITDA for the quarter was $179 million, impacted by currency headwinds of approximately $25 million [64][70] - Adjusted gross margin for the quarter was 59.7%, flat compared to Q2 2022 [64] Business Line Data and Key Metrics Changes - Vision Care revenue was $646 million, increasing by 12% on a constant currency basis, driven by growth in both consumer and lens portfolios [24] - Surgical segment revenue was $195 million, an increase of 7% on a constant currency basis, with consumables growing by 11% [27] - Pharma segment revenues were $194 million, representing constant currency growth of 16%, with strong performance across all portfolios [28] Market Data and Key Metrics Changes - The China business grew 24% on a constant currency basis, contributing approximately 200 basis points to the overall second quarter growth [29] - The U.S. lens portfolio was negatively impacted by disruptions related to a new warehouse management system, particularly affecting the Ultra lens family [60] Company Strategy and Development Direction - The company is focused on improving supply chain efficiency and product delivery, with a roadmap to accelerate growth and enhance capabilities [15][80] - Investments in R&D are expected to be approximately 8% of revenue, with a commitment to support product launches and innovation [71] - The company aims to be a comprehensive eye care provider, not solely focused on pharmaceuticals, with a balanced approach across all business segments [44][135] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing supply challenges but expressed confidence in resolving these issues over time [40][141] - The company raised its revenue guidance for 2023 to a range of $3.95 billion to $4 billion, reflecting a constant currency growth rate of approximately 6.5% to 7.5% [67][68] - Management is optimistic about the upcoming product launches, particularly MIEBO, which is expected to be a significant contributor to growth [45][151] Other Important Information - The company announced the strategic acquisition of Blink to expand its OTC eye drop portfolio, although it is not expected to have a meaningful impact on 2023 financial results [59][122] - The XIIDRA transaction is expected to close by the end of 2023, subject to regulatory approvals [41] Q&A Session Summary Question: What is the quantifiable impact of supply challenges and the timing for resolution? - Management indicated that the supply chain issues have led to a quantifiable impact of approximately 600 basis points on the lens business growth, which would have been around 10% without these challenges [55][141] Question: How is the company addressing the supply chain issues? - The company is working to validate second vendors and has been engaging in spot buying to secure necessary components, although this has led to higher costs and margin pressure [54][141] Question: What are the expectations for the MIEBO launch? - The MIEBO launch is anticipated to be significant, with management expressing optimism about its market potential and the differentiated treatment it offers for dry eye disease [45][119] Question: How should investors think about growth in volumes versus pricing? - Management noted that the majority of growth in Q2 was driven by volume rather than price, indicating a focus on sustainable growth through volume increases [137]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other juri ...

Bausch + Lomb Corporation (NYSE:BLCO) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Allison Ryan - ED, IR Brent Saunders - CEO and Chairman Sam Eldessouky - EVP and CFO Conference Call Participants Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Cecilia Furlong - Morgan Stanley Craig Bijou - Bank of America Merrill Lynch Operator Good morning, and welcome to the Bausch + Lomb's First Quarter 2023 Earnings Call. All ...

All allocations and estimates in these Condensed Consolidated Financial Statements are based on assumptions that management believes are reasonable. On an ongoing basis, management reviews its allocations and estimates to ensure that these allocations and estimates appropriately reflect changes in the Company's business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company's bu ...

Bausch + Lomb Corporation (NYSE:BLCO) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Relations Joe Papa – Chief Executive Officer Brent Saunders – Incoming Chief Executive Officer and Chairman of the Board of Directors Sam Eldessouky – Executive Vice President and Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Cecilia Furlong – Morgan Stanley Matt Miksic – Barclays Vijay Kumar – Evercore ISI Joanne Wuensch – Citi ...

BAUSCH+LOMB This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forwardlooking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2023 first quarter outlook and assumption thereof), the planned spin-off or separation of the Company from Bausch Health Companies Inc. ("BHC ...

Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Canada 98-1613662 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K Commission File Number: 001-41380 Registrant's telephone number, including area code (905) 695-7700 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, No Par ...

1. Third party market research and management estimates. Contact lens includes: sales from contact lenses, lens care solutions, and off-the-shelf eye care products; Consumer includes: sales from eye drops and eye vitamins 2. Third party market research and management estimates. AMD includes: sales from products for the treatment of wet age-related macular degeneration ("AMD") and dry AMD; Glaucoma includes: sales from products for the treatment of glaucoma; Dry Eye / Other includes: sales from products for ...

3Q22 Financial Results Forward-Looking Statements 1 This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forwardlooking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2022 full-year guidance, expectations regarding adjusted gross margin and expected organic growth), t ...

Bausch + Lomb Corporation (NYSE:BLCO) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Alison Ryan - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Zack Weiner - Jefferies Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Operator Good morning, and welcome to the Bausch + ...